Quick Answer
Monte Rosa Therapeutics, Inc. reported Net Income of -$38.63 million for fiscal year 2025.
Monte Rosa Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$38.63M | +46.9% |
| 2024 | -$72.70M | +46.3% |
| 2023 | -$135.35M | -24.7% |
| 2022 | -$108.50M | -46.7% |
| 2021 | -$73.96M | -106.1% |
| 2020 | -$35.88M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$27.08M | -13.5% | -120.3% |
| June 30, 2025 | -$12.29M | +59.4% | -126.2% |
| March 31, 2025 | $46.88M | +246.7% | +296.5% |
| September 30, 2024 | -$23.86M | +31.6% | +21.3% |
| June 30, 2024 | -$30.31M | +13.8% | +5.2% |
| March 31, 2024 | -$31.97M | +0.2% | +8.4% |
| September 30, 2023 | -$34.88M | -27.7% | +0.8% |
| June 30, 2023 | -$35.18M | -32.9% | -9.8% |
- Monte Rosa Therapeutics, Inc. showed an increase of +46.9% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Monte Rosa Therapeutics, Inc.’s net income has declined by 7.7% (from -$35.88 million to -$38.63 million).
- The most recent figure is from Monte Rosa Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: